Adoptive Cell therapy for sarcoma

[D.ap]

Adoptive cell therapy for sarcoma

Immunotherapy. Author manuscript; available in PMC 2015 Nov 1.

Published in final edited form as:

Immunotherapy. 2015; 7(1): 21–35.
doi: 10.2217/imt.14.98

PMCID: PMC4331182

NIHMSID: NIHMS655407


Adoptive cell therapy for sarcoma


Melinda Mata1,2,3,4 and Stephen Gottschalk*,1,2,3,4

Author information ► Copyright and License information ►
The publisher's final edited version of this article is available at Immunotherapy

Abstract


Current therapy for sarcomas, though effective in treating local disease, is often ineffective for patients with recurrent or metastatic disease. To improve outcomes, novel approaches are needed and cell therapy has the potential to meet this need since it does not rely on the cytotoxic mechanisms of conventional therapies. The recent successes of T-cell therapies for hematological malignancies have led to renewed interest in exploring cell therapies for solid tumors such as sarcomas. In this review, we will discuss current cell therapies for sarcoma with special emphasis on genetic approaches to improve the effector function of adoptively transferred cells.

Keywords: cancer immunotherapy, cell therapy, gene transfer, sarcoma

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331182/